Get started
Author

A. Eremeeva

Observed names: A Eremeeva, A. V. Eremeeva, Anna Eremeeva, Anna V. Eremeeva
Institution: BIOCAD (Russia)
ORCID: 0000-0002-1267-0074
Observed ORCID: 0000-0002-1267-0074
OpenAlex ID: A5102809147
Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults.
2020 · Shandor Erdes, Evgeny Nasonov, et al. · PubMed · 40
The Results of a Phase Iii Comparative Clinical Trial of Rituximab (acellbia® and Mabthera®) in Rheumatoid Arthritis (the Biora Study)
2016 · E. L. Nasonov, E. V. Zonova, et al. · Rheumatology Science and Practice · 35
Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study
2020 · T. V. Korotaeva, V. I. Mazurov, et al. · Rheumatology Science and Practice · 23
Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA
2020 · V. I. Mazurov, I. Z. Gaydukova, et al. · Rheumatology Science and Practice · 19
PDF
Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study
2021 · V. I. Mazurov, E. G. Zotkin, et al. · Rheumatology Science and Practice · 18
PDF
Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA
2020 · V. I. Mazurov, Sh. F. Erdes, et al. · Modern Rheumatology Journal · 17
PDF
Effectiveness and safety of levilimab in combination with methotrexate in treatment of patients with active rheumatoid arthritis resistant to methotrexate monotherapy (double-blinded randomized placebo controlled phase III clinical study SOLAR)
2021 · V. I. Mazurov, M. A. Korolev, et al. · Modern Rheumatology Journal · 14
PDF
Rheumatic manifestations of hypothyroidism
2017 · L. V. Teplova, A. V. Eremeeva, et al. · Modern Rheumatology Journal · 14
PDF
A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study
2019 · Alexander M. Lila, Vadim I. Mazurov, et al. · Rheumatology International · 12
Ab0540 Comparison of Eq-5d Health Status in Psoriatic Arthritis Patients With or Without Axial Disease: Results of Subanalysis of the Patera Study
2021 · I. Gaydukova, T. Korotaeva, et al. · Annals of the Rheumatic Diseases · 11
PDF
Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study
2021 · T. V. Korotaeva, V. I. Mazurov, et al. · Rheumatology Science and Practice · 11
PDF
OP0028 Efficacy and safety of bcd-085, a novel il-17 inhibitor, in ankylosing spondylitis. results of phase 2 clinical study
2018 · V. Mazurov, S. Erdes, et al. · Annals of the Rheumatic Diseases · 10
PDF
FRI0224 Comparison of Efficacy and Safety of Rituximab Biosimilar, BCD-020, and Innovator Rituximab in Patients with Active Rheumatoid Arthritis Refractory To TNFA Inhibitors
2016 · A. Eremeeva, E. Chernyaeva, et al. · Annals of the Rheumatic Diseases · 7
Op0226 Netakimab Decreases Disease Activity in Patients With Psoriatic Arthritis: Results From a Randomized Double-blind Phase 3 Clinical Trial (patera)
2020 · T. Korotaeva, I. Gaydukova, et al. · Annals of the Rheumatic Diseases · 6
PDF
Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies)
2017 · D. E. Karateev, V. I. Mazurov, et al. · Modern Rheumatology Journal · 6
PDF
FRI0010 Pharmacokinetics, Safety and Tolerance of BCD-085, A Novel IL-17 Inhibitor, Based on The Results of Phase 1 Clinical Study in Healthy Volunteers
2016 · E. Chernyaeva, A. Eremeeva, et al. · Annals of the Rheumatic Diseases · 6
Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR
2024 · V. I. Mazurov, E. L. Nasonov, et al. · Doklady Biochemistry and Biophysics · 5
Pos1043 Netakimab Reduces Psoriatic Arthritis Activity in Patients With or Without Axial Disease: Subanalysis of the Patera Study
2021 · T. Korotaeva, I. Gaydukova, et al. · Annals of the Rheumatic Diseases · 4
PDF
Op0232 Netakimab Reduces the Disease Activity of Radiographic Axial Spondyloarthritis. Results of Astera Study
2019 · Inna Gaydukova, V Mazurov, et al. · Annals of the Rheumatic Diseases · 4
PDF
Pos0928 Netakimab Efficacy in Anti-tnf-naive and Anti-tnf-experienced Patients With Active Ankylosing Spondylitis: Results of Subanalysis of Phase 3 Astera Trial
2021 · S. Erdes, V. Mazurov, et al. · Annals of the Rheumatic Diseases · 3
PDF
Fri0391 Netakimab Improves Patient-related Outcomes in Patients With Radiological Axial Spondyloarthritis: Results From Randomised Phase 3 Trial (astera)
2019 · Inna Gaydukova, V Mazurov, et al. · Annals of the Rheumatic Diseases · 3
PDF
Fri0412 Spinal and Sacroiliac Joints Inflammation in Patients With Radiographic Axial Spondyloarthritis Treated With Netakimab – 16-weeks Results of Multicenter, Randomized, Double-blind, Placebo-controlled Phase Iii Astera Study
2019 · Alexander Smirnov, Inna Gaydukova, et al. · Annals of the Rheumatic Diseases · 3
PDF
SAT0040 Safety, tolerability, pharmacokinetics and pharmacodynamics of bcd-089, novel monoclonal anti-il-6 receptor antibody: results from the first-in-human single dose escalation study in healthy volunteers
2018 · P. Khlyabova, A. Eremeeva, et al. · Annals of the Rheumatic Diseases · 2
PDF
THU0193 Efficacy and safety of bcd-055 (INFLIXIMAB BIOSIMILAR) in rheumatoid arthritis. results of bcd-055–3/lira phase 3 clinical study
2018 · A. Lila, L. Denisov, et al. · Annals of the Rheumatic Diseases · 2
PDF
FRI0208 Comparison of efficacy, safety and pharmacokinetics of infliximab biosimilar (BCD-055) and innovator infliximab
2017 · L Denisov, I Gordeev, et al. · Annals of the Rheumatic Diseases · 2
PDF
Works count: 37
Citation count: 284
H-index: 11
I10-index: 12
Year
Topic
Type